Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) EBITDA (2020 - 2024)

Immuneering has reported EBITDA over the past 5 years, most recently at -$18.1 million for Q4 2024.

  • Quarterly results put EBITDA at -$18.1 million for Q4 2024, down 19.68% from a year ago — trailing twelve months through Dec 2024 was -$61.0 million (down 14.21% YoY), and the annual figure for FY2025 was -$55.9 million, up 8.34%.
  • EBITDA for Q4 2024 was -$18.1 million at Immuneering, down from -$14.6 million in the prior quarter.
  • Over the last five years, EBITDA for IMRX hit a ceiling of -$3.6 million in Q2 2020 and a floor of -$18.1 million in Q4 2024.
  • Median EBITDA over the past 5 years was -$12.6 million (2023), compared with a mean of -$11.2 million.
  • Biggest five-year swings in EBITDA: plummeted 121.47% in 2021 and later increased 1.7% in 2023.
  • Immuneering's EBITDA stood at -$5.8 million in 2020, then crashed by 85.55% to -$10.8 million in 2021, then dropped by 21.28% to -$13.1 million in 2022, then dropped by 14.9% to -$15.1 million in 2023, then dropped by 19.68% to -$18.1 million in 2024.
  • The last three reported values for EBITDA were -$18.1 million (Q4 2024), -$14.6 million (Q3 2024), and -$14.1 million (Q2 2024) per Business Quant data.